Developer docs
API playgroundTry for free, no card

Search company profiles

Omnigen

Full company profile

uuid00267gt

Namestring
Omnigen
Legal namestring
OMNIGEN ΒΙΟΤΕΧΝΟΛΟΓΙΚΕΣ ΕΦΑΡΜΟΓΕΣ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ
Websiteurl
omnigen.gr
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Omnigen SA is a privately held Greek biotechnology company, incorporated as a Societe Anonyme and headquartered in Marousi, Athens, that has operated since 2006 in stem cell cryopreservation, cell therapies, and regenerative medicine. The company functions as a family cord blood and tissue bank, isolating and cryopreserving hematopoietic stem cells from umbilical cord blood (OMNI-BLOOD) and mesenchymal stem cells from umbilical cord tissue (OMNI-CORD), and offers a combined bundle (OMNI-PLUS). Operations run through GMP/GLP-compliant laboratories with cryopreservation at temperatures below -150°C in monitored tanks, using ISBT-128 international coding for sample traceability and a continuing-storage contractual clause that guarantees transfer to another licensed EU bank upon termination.

The company holds several first-mover regulatory positions in Greece: the first private cord blood bank licensed by the Ministry of Health (License C2c/31238, renewed June 2026), the first bank approved by the National Transplant Organization (EOM) for tissue cryopreservation, and the first Greek biobank recognized by the European body for Tissue and Cell Banks (EU TE Code GR012775). It is accredited to ISO 9001:2015 by Lloyd's Register, to ELOT EN ISO/IEC 17025:2005 under ESYD (No. 560), and operates quality systems harmonized with FACT and JACIE international standards. Beyond storage, Omnigen offers an in-house diagnostic portfolio: Thrombophilia Screening via Real-Time PCR TaqMan genotyping, Cystic Fibrosis Examination via direct DNA sequencing and an Abbott CFTR assay covering 202 mutations, and, through a partnership with Veragen/Veracity, non-invasive prenatal testing (VERAGEN) that simultaneously screens for aneuploidies, microdeficiencies, and gene mutations.

The commercial model is direct-to-consumer and sales-led, targeting expectant parents and prenatal patients through a bilingual website (Greek/English), Facebook and YouTube channels, email marketing, and on-site consultations at the Marousi office or at customer locations. Healthcare providers (obstetricians and hospitals) act as referral partners and coordinate sample collection at the point of childbirth. Revenue is generated via multi-year subscription contracts (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS) billed on multi-year cadences plus professional-services fees for diagnostic testing. Payments are accepted by bank deposit, cash, credit card with up to six interest-free installments, and online payment via Alpha e-Commerce. EU ESPA funding for the 2021-2027 period is disclosed, but no headcount growth, funding rounds, M&A, or revenue figures are publicly available.

Short descriptiontext

Omnigen is a Greece-based, licensed family cord blood and tissue bank that processes and cryopreserves umbilical cord blood and tissue stem cells (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS), and serves expectant parents and prenatal healthcare patients with diagnostic services and NIPT screening in partnership with Veragen.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cord blood banking, stem cell cryopreservation, regenerative medicine, prenatal diagnostic testing, cell therapy services
Industry3 codes
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)
NAICS code2 codes
  • Blood and Organ Banks621991
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
Product category
Stem Cell Banking and Cryopreservation Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Stem Cell Cryopreservation Services
TypeSubscription Recurring
Description

Core revenue stream from processing and cryopreserving hematopoietic stem cells from umbilical cord blood and cord tissue. Services include collection kit provision, transportation, processing, cryopreservation, and ongoing storage for the contract duration.

omnigen.gr
2Diagnostic Testing Services
TypeProfessional Services
Description

Revenue from thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAgene) services performed in their accredited laboratories.

omnigen.gr
3OMNI-BLOOD, OMNI-CORD, OMNI-PLUS Packages
TypeSubscription Recurring
Description

Different service packages offering cord blood storage, cord tissue storage, or combined storage solutions at varying price points with the OMNI-PLUS package offering special pricing for combined services.

omnigen.gr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details3 tiers
1OMNI-BLOOD - Cord Blood Collection and Storage
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Includes parents' information and supply with collection kit, transportation in special insulated package with temperature monitoring, processing in modern laboratories, cryopreservation in high quality cryobag, storage in tanks with remote alarm and 24-hour monitoring, traceability from kit supply to distribution, and international ISBT-128 coding.

omnigen.gr
2OMNI-CORD - Umbilical Cord Tissue Storage
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Transportation in special insulated package, processing of umbilical cord blood and tissue, storage of valuable multipotent mesenchymal cells for future use.

omnigen.gr
3OMNI-PLUS - Combined Storage Package
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Combination package of OMNI-BLOOD and OMNI-CORD services at a special price. Includes transportation and processing of both samples, free transportation of both samples in case of illness, and access to both hematopoietic and mesenchymal stem cells for regenerative medicine.

omnigen.gr
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 4 records shown
1OMNI-BLOOD
Description

Cord blood collection service including transportation, processing, cryopreservation and storage of umbilical cord blood stem cells.

omnigen.gr
+3 more records
Core offering1 text field

Omnigen is a licensed Greek cord blood bank that provides collection, processing, cryopreservation, and long-term storage of hematopoietic stem cells from umbilical cord blood and mesenchymal stem cells from umbilical cord tissue for family use. The company also offers diagnostic laboratory services including thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAGEN) for expectant parents.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 59% lower likelihood of developing serious adverse events (GVHD) in recipients of umbilical cord blood transplants compared to bone marrow transplants from siblings
+2 more records
Product overview1 text field

Omnigen is a licensed cord blood bank and biotechnology company offering a portfolio of stem cell banking and diagnostic services. The core offering consists of OMNI-BLOOD (cord blood stem cell cryopreservation), OMNI-CORD (umbilical cord tissue storage for mesenchymal stem cells), and OMNI-PLUS (a combined package of both services). The company also provides diagnostic laboratory services including Thrombophilia Screening using Real-Time PCR methodology, Cystic Fibrosis Examination through CFTR gene mutation analysis, and VERAGEN Non-Invasive Prenatal Testing for aneuploidies, microdeficiencies, and gene mutations. The company operates as a family cord blood storage bank licensed by the Greek Ministry of Health, serving clients in Greece with collection, processing, cryopreservation, and storage services for umbilical cord blood and tissue.

Product and service6 records
1OMNI-BLOOD
CategoryStem Cell Cryopreservation
Description

Cord blood collection and cryopreservation service that isolates and cryopreserves hematopoietic stem cells from umbilical cord blood, processed in modern laboratories and stored at temperatures below -150°C in high-quality cryobags with 24-hour monitoring and remote alarm systems. Targets expectant parents in Greece seeking family banking for potential future therapeutic use.

2OMNI-CORD
CategoryStem Cell Cryopreservation
Description

Umbilical cord tissue storage service that processes and cryopreserves the cord tissue to isolate and store valuable multipotent mesenchymal cells for future medical use in regenerative medicine applications. Targets expectant parents seeking additional stem cell sources beyond cord blood.

3OMNI-PLUS
CategoryStem Cell Cryopreservation Bundle
Description

Combined cryopreservation package that includes both OMNI-BLOOD (umbilical cord blood stem cells) and OMNI-CORD (umbilical cord tissue) services at a special price, providing both hematopoietic and mesenchymal stem cells available for regenerative medicine. Includes free transportation of both samples in case of illness.

4Thrombophilia Screening
CategoryDiagnostic Testing
Description

Genetic diagnostic test that detects thrombophilic factors using Real-Time PCR methodology (TaqMan assay genotyping) to identify hypercoagulability conditions in blood circulation that can lead to clot formation and pregnancy complications. Targets pregnant women and individuals with family history of clotting disorders.

5Cystic Fibrosis Examination
CategoryDiagnostic Testing
Description

Genetic screening test for cystic fibrosis that detects pathogenic mutations in the CFTR gene through direct DNA sequencing and the Abbott Cystic Fibrosis Genotyping Assay, covering 202 pathogenic mutations representing 90% of recorded mutations in international databases. Targets couples planning for or during pregnancy to assess carrier status.

6VERAGEN (Non-Invasive Prenatal Testing)
CategoryDiagnostic Testing
Description

Non-invasive prenatal test (NIPT) that simultaneously screens for aneuploidies, microdeficiencies, and gene mutations from a maternal blood sample, with results delivered in 4-7 business days. The test uses maternal blood and paternal oral swab samples collected by doctors at least 10 weeks into pregnancy. The only NIPT in the Greek market combining all three screening types.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

Omnigen offers VERAgene non-invasive prenatal testing (NIPT) for aneuploidies, microdeficiencies, and gene mutations. This is the only non-invasive prenatal test that can simultaneously screen for these three types of genetic conditions. Omnigen performs the laboratory analysis of maternal blood samples and paternal oral swabs collected by doctors at least 10 weeks into pregnancy.

2Theodoros Moumouris
Strategic tierMinorTypeOthers
Description

Signed official GMP compliance document dated June 28, 2011, related to the company's laboratory operations and regulatory compliance.

omnigen.gr
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based private cord blood and tissue bank offering family stem cell storage across multiple countries in Europe. Directly comparable to Omnigen in business model (B2C family banking, recurring storage contracts), accreditation stack, and service mix including NIPT-adjacent diagnostics.

TypeBroad incumbent
Description

US-listed public cord blood bank with decades of operating history and a broader product portfolio across family banking and therapeutic services. Comparable as a scaled, publicly disclosed private-market peer in the family cord blood banking category.

3StemCare
TypeRegional player
Description

Nordic-focused private cord blood and tissue stem cell bank serving Northern European markets. Comparable to Omnigen in service offering and family banking model, but operating in a different geography from Omnigen's Greek market.

TypeDirect peer
Description

UK-based private stem cell bank offering cord blood and tissue storage with multi-year contracts. Directly comparable to Omnigen in operating model and customer segment (expectant parents seeking family banking).

TypeDirect peer
Description

Greek biotechnology company operating a stem cell and cord blood bank in Thessaloniki. Directly comparable to Omnigen as a Greek competitor in the same cord blood banking category, addressing the same domestic customer base.

TypeDirect peer
Description

One of Europe's largest private stem cell banks, offering cord blood, cord tissue, and other cell storage with multi-year contracts. Closely comparable to Omnigen on service model, customer base (expectant parents), and regulatory positioning across European markets.

TypeDirect peer
Description

UK-based private cord blood stem cell bank serving expectant parents in the UK and internationally. Closely comparable to Omnigen as a direct-to-consumer family cord blood storage operator with multi-year storage contracts and obstetrician referral channels.

TypeDirect peer
Description

US private cord blood bank offering family storage of umbilical cord blood and tissue. Comparable to Omnigen as a direct-to-consumer private cord blood storage operator with subscription-style contracts.

TypeBroad incumbent
Description

US-based cord blood and cord tissue bank (part of Revvity/PerkinElmer) offering family stem cell storage. Comparable as a large incumbent in the same product category with broader portfolio scale and brand recognition than Omnigen.

TypeBroad incumbent
Description

One of the largest US family cord blood banks, now part of California Cryobank. Comparable as a broad incumbent in the same family cord blood banking category with significantly larger scale and brand reach than Omnigen.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Omnigen

Stem Cell Banking and Cryopreservation Servicesomnigen.gr

Omnigen is a Greece-based, licensed family cord blood and tissue bank that processes and cryopreserves umbilical cord blood and tissue stem cells (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS), and serves expectant parents and prenatal healthcare patients with diagnostic services and NIPT screening in partnership with Veragen.

What Omnigen does

Omnigen SA is a privately held Greek biotechnology company, incorporated as a Societe Anonyme and headquartered in Marousi, Athens, that has operated since 2006 in stem cell cryopreservation, cell therapies, and regenerative medicine. The company functions as a family cord blood and tissue bank, isolating and cryopreserving hematopoietic stem cells from umbilical cord blood (OMNI-BLOOD) and mesenchymal stem cells from umbilical cord tissue (OMNI-CORD), and offers a combined bundle (OMNI-PLUS). Operations run through GMP/GLP-compliant laboratories with cryopreservation at temperatures below -150°C in monitored tanks, using ISBT-128 international coding for sample traceability and a continuing-storage contractual clause that guarantees transfer to another licensed EU bank upon termination.

The company holds several first-mover regulatory positions in Greece: the first private cord blood bank licensed by the Ministry of Health (License C2c/31238, renewed June 2026), the first bank approved by the National Transplant Organization (EOM) for tissue cryopreservation, and the first Greek biobank recognized by the European body for Tissue and Cell Banks (EU TE Code GR012775). It is accredited to ISO 9001:2015 by Lloyd's Register, to ELOT EN ISO/IEC 17025:2005 under ESYD (No. 560), and operates quality systems harmonized with FACT and JACIE international standards. Beyond storage, Omnigen offers an in-house diagnostic portfolio: Thrombophilia Screening via Real-Time PCR TaqMan genotyping, Cystic Fibrosis Examination via direct DNA sequencing and an Abbott CFTR assay covering 202 mutations, and, through a partnership with Veragen/Veracity, non-invasive prenatal testing (VERAGEN) that simultaneously screens for aneuploidies, microdeficiencies, and gene mutations.

The commercial model is direct-to-consumer and sales-led, targeting expectant parents and prenatal patients through a bilingual website (Greek/English), Facebook and YouTube channels, email marketing, and on-site consultations at the Marousi office or at customer locations. Healthcare providers (obstetricians and hospitals) act as referral partners and coordinate sample collection at the point of childbirth. Revenue is generated via multi-year subscription contracts (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS) billed on multi-year cadences plus professional-services fees for diagnostic testing. Payments are accepted by bank deposit, cash, credit card with up to six interest-free installments, and online payment via Alpha e-Commerce. EU ESPA funding for the 2021-2027 period is disclosed, but no headcount growth, funding rounds, M&A, or revenue figures are publicly available.

Omnigen firmographics

Firmographics
Name
Omnigen
Legal name
OMNIGEN ΒΙΟΤΕΧΝΟΛΟΓΙΚΕΣ ΕΦΑΡΜΟΓΕΣ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ
Website
https://omnigen.gr
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Omnigen is a Greece-based, licensed family cord blood and tissue bank that processes and cryopreserves umbilical cord blood and tissue stem cells (OMNI-BLOOD, OMNI-CORD, OMNI-PLUS), and serves expectant parents and prenatal healthcare patients with diagnostic services and NIPT screening in partnership with Veragen.
Ownership category
akta.pro rank

Omnigen industry classification

Industry
Product category
Stem Cell Banking and Cryopreservation Services
NAICS
Blood and Organ Banks (621991), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAFAMAG
Transfusion Medicine & Immunohematology (Blood Bank)

Keywords

  • Cord blood banking
  • Stem cell cryopreservation
  • Regenerative medicine
  • Prenatal diagnostic testing
  • Cell therapy services

Where Omnigen is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices1 record

Markets served

Omnigen business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Stem Cell Cryopreservation Services: Core revenue stream from processing and cryopreserving hematopoietic stem cells from umbilical cord blood and cord tissue. Services include collection kit provision, transportation, processing, cryopreservation, and ongoing storage for the contract duration.
  2. Diagnostic Testing Services: Revenue from thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAgene) services performed in their accredited laboratories.
  3. OMNI-BLOOD, OMNI-CORD, OMNI-PLUS Packages: Different service packages offering cord blood storage, cord tissue storage, or combined storage solutions at varying price points with the OMNI-PLUS package offering special pricing for combined services.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractOMNI-BLOOD - Cord Blood Collection and Storage
SubscriptionMulti-year contractOMNI-CORD - Umbilical Cord Tissue Storage
SubscriptionMulti-year contractOMNI-PLUS - Combined Storage Package

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Omnigen product offering

Product offering

Core offering

Omnigen is a licensed Greek cord blood bank that provides collection, processing, cryopreservation, and long-term storage of hematopoietic stem cells from umbilical cord blood and mesenchymal stem cells from umbilical cord tissue for family use. The company also offers diagnostic laboratory services including thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAGEN) for expectant parents.

Product overview

Omnigen is a licensed cord blood bank and biotechnology company offering a portfolio of stem cell banking and diagnostic services. The core offering consists of OMNI-BLOOD (cord blood stem cell cryopreservation), OMNI-CORD (umbilical cord tissue storage for mesenchymal stem cells), and OMNI-PLUS (a combined package of both services). The company also provides diagnostic laboratory services including Thrombophilia Screening using Real-Time PCR methodology, Cystic Fibrosis Examination through CFTR gene mutation analysis, and VERAGEN Non-Invasive Prenatal Testing for aneuploidies, microdeficiencies, and gene mutations. The company operates as a family cord blood storage bank licensed by the Greek Ministry of Health, serving clients in Greece with collection, processing, cryopreservation, and storage services for umbilical cord blood and tissue.

Differentiator

Problem solved

Functional benefit

Brands

  • OMNI-BLOOD: Cord blood collection service including transportation, processing, cryopreservation and storage of umbilical cord blood stem cells.
  • OMNI-CORD
  • OMNI-PLUS
  • VERAGEN

Products and services

  • OMNI-BLOOD Cord blood collection and cryopreservation service that isolates and cryopreserves hematopoietic stem cells from umbilical cord blood, processed in modern laboratories and stored at temperatures below -150°C in high-quality cryobags with 24-hour monitoring and remote alarm systems. Targets expectant parents in Greece seeking family banking for potential future therapeutic use.
  • OMNI-CORD Umbilical cord tissue storage service that processes and cryopreserves the cord tissue to isolate and store valuable multipotent mesenchymal cells for future medical use in regenerative medicine applications. Targets expectant parents seeking additional stem cell sources beyond cord blood.
  • OMNI-PLUS Combined cryopreservation package that includes both OMNI-BLOOD (umbilical cord blood stem cells) and OMNI-CORD (umbilical cord tissue) services at a special price, providing both hematopoietic and mesenchymal stem cells available for regenerative medicine. Includes free transportation of both samples in case of illness.
  • Thrombophilia Screening Genetic diagnostic test that detects thrombophilic factors using Real-Time PCR methodology (TaqMan assay genotyping) to identify hypercoagulability conditions in blood circulation that can lead to clot formation and pregnancy complications. Targets pregnant women and individuals with family history of clotting disorders.
  • Cystic Fibrosis Examination Genetic screening test for cystic fibrosis that detects pathogenic mutations in the CFTR gene through direct DNA sequencing and the Abbott Cystic Fibrosis Genotyping Assay, covering 202 pathogenic mutations representing 90% of recorded mutations in international databases. Targets couples planning for or during pregnancy to assess carrier status.
  • VERAGEN (Non-Invasive Prenatal Testing) Non-invasive prenatal test (NIPT) that simultaneously screens for aneuploidies, microdeficiencies, and gene mutations from a maternal blood sample, with results delivered in 4-7 business days. The test uses maternal blood and paternal oral swab samples collected by doctors at least 10 weeks into pregnancy. The only NIPT in the Greek market combining all three screening types.

Quantifiable outcome

  • 59% lower likelihood of developing serious adverse events (GVHD) in recipients of umbilical cord blood transplants compared to bone marrow transplants from siblings
  • +2 more outcomes

Companies that use Omnigen

Customer profile

Segments3 records

Ideal customer profiles2 records

Omnigen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Omnigen partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Veragen / VeracitycoreTechnology or IntegrationOmnigen offers VERAgene non-invasive prenatal testing (NIPT) for aneuploidies, microdeficiencies, and gene mutations. This is the only non-invasive prenatal test that can simultaneously screen for these three types of genetic conditions. Omnigen performs the laboratory analysis of maternal blood samples and paternal oral swabs collected by doctors at least 10 weeks into pregnancy.
  • Theodoros MoumourisminorOthersSigned official GMP compliance document dated June 28, 2011, related to the company's laboratory operations and regulatory compliance.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Omnigen competitors and assessment

Company assessment

Direct peers

  • Cells4Life: UK-based private cord blood and tissue bank offering family stem cell storage across multiple countries in Europe. Directly comparable to Omnigen in business model (B2C family banking, recurring storage contracts), accreditation stack, and service mix including NIPT-adjacent diagnostics.
  • Precious Cells International: UK-based private stem cell bank offering cord blood and tissue storage with multi-year contracts. Directly comparable to Omnigen in operating model and customer segment (expectant parents seeking family banking).
  • Biohellenika: Greek biotechnology company operating a stem cell and cord blood bank in Thessaloniki. Directly comparable to Omnigen as a Greek competitor in the same cord blood banking category, addressing the same domestic customer base.
  • Future Health Biobank: One of Europe's largest private stem cell banks, offering cord blood, cord tissue, and other cell storage with multi-year contracts. Closely comparable to Omnigen on service model, customer base (expectant parents), and regulatory positioning across European markets.
  • Smart Cells International: UK-based private cord blood stem cell bank serving expectant parents in the UK and internationally. Closely comparable to Omnigen as a direct-to-consumer family cord blood storage operator with multi-year storage contracts and obstetrician referral channels.
  • AlphaCord: US private cord blood bank offering family storage of umbilical cord blood and tissue. Comparable to Omnigen as a direct-to-consumer private cord blood storage operator with subscription-style contracts.

Broad incumbents

  • Cryo-Cell International: US-listed public cord blood bank with decades of operating history and a broader product portfolio across family banking and therapeutic services. Comparable as a scaled, publicly disclosed private-market peer in the family cord blood banking category.
  • ViaCord: US-based cord blood and cord tissue bank (part of Revvity/PerkinElmer) offering family stem cell storage. Comparable as a large incumbent in the same product category with broader portfolio scale and brand recognition than Omnigen.
  • Cord Blood Registry (CBR): One of the largest US family cord blood banks, now part of California Cryobank. Comparable as a broad incumbent in the same family cord blood banking category with significantly larger scale and brand reach than Omnigen.

Regional players

  • StemCare: Nordic-focused private cord blood and tissue stem cell bank serving Northern European markets. Comparable to Omnigen in service offering and family banking model, but operating in a different geography from Omnigen's Greek market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Omnigen social profiles

Digital presence

Omnigen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Omnigen leadership team

Management profile

Number of profiles

Omnigen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Omnigen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omnigen

What does Omnigen do?

Omnigen is a licensed Greek cord blood bank that provides collection, processing, cryopreservation, and long-term storage of hematopoietic stem cells from umbilical cord blood and mesenchymal stem cells from umbilical cord tissue for family use. The company also offers diagnostic laboratory services including thrombophilia screening, cystic fibrosis genetic testing, and non-invasive prenatal testing (VERAGEN) for expectant parents.

Is Omnigen a public or private company?

Omnigen is a private company. It is classified as unknown and is currently operating.

When was Omnigen founded?

Omnigen was founded in 2006. It employs 1 to 10 people.

Where is Omnigen based?

Omnigen is headquartered in Athens, Greece, in the Europe region.

How does Omnigen make money?

Three revenue lines are on record. Stem Cell Cryopreservation Services are the primary driver. The others are diagnostic Testing Services and OMNI-BLOOD, OMNI-CORD, OMNI-PLUS Packages.

Who are Omnigen's main competitors?

Direct peers on record are Cells4Life, Precious Cells International, Biohellenika, Future Health Biobank, Smart Cells International and AlphaCord. Broad incumbents are Cryo-Cell International, ViaCord and Cord Blood Registry (CBR). StemCare is listed as a regional player.

Does Omnigen have an API?

No public API is recorded for Omnigen.

What industry is Omnigen in?

Omnigen's product category is Stem Cell Banking and Cryopreservation Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621991 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales